Mephedrone and Nicotine: Oxidative Stress and Behavioral Interactions in Animal Models

Barbara Budzynska · Anna Boguszewska-Czubara · Marta Kruk-Slomka · Jacek Kurzepa · Grazyna Biala

Received: 22 December 2014 / Revised: 12 March 2015 / Accepted: 30 March 2015 / Published online: 11 April 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract The purpose of our experiment was to examine the influence of co-administration of nicotine and mephedrone on anxiety-like behaviors, cognitive processes and the nicotine-induced behavioral sensitization as well as processes connected with induction of oxidative stress in the brain of male Swiss mice. The results revealed that co-administration of subthreshold doses of mephedrone and nicotine (0.05 mg/kg each) exerted marked anxiogenic profile in the elevated plus maze and displayed pro-cognitive action in the passive avoidance paradigm (nicotine 0.05 mg/kg and mephedrone 2.5 mg/kg). Furthermore, one of the main findings of the present study was that mephedrone, administered alone at the dose not affecting locomotor activity of mice (1 mg/kg), enhanced the expression of nicotine-induced locomotor sensitization. Moreover, mephedrone administered with nicotine decreased general antioxidant status and catalase activity as well as antioxidant enzymes activity in the hippocampus and prefrontal cortex and increased concentration of malondialdehyde, an indicator of lipid peroxidation processes. Considering the likelihood that mephedrone is taken as a part of polydrug combination with nicotine, the effects of this combination on mammalian organisms have been confirmed in our study. Understanding the consequences of co-administration of psychoactive substances on the central nervous system and oxidative processes in the brain provide the important toxicological significance, and may be useful in polydrug intoxication treatment.

Keywords Mephedrone · Nicotine · Oxidative stress · Memory · Anxiety · Locomotor sensitization

Introduction

The use of different types of club drugs, especially by young people, has been considered an ignored phenomenon for a long time. Legal highs or club drugs, various kinds of products containing psychoactive substances, were often taken as a part of the nightclub scene with alcohol, marijuana or amphetamines. One such club drug is mephedrone (RS)-1-(4-methylphenyl)-2-metyloaminopropan-1-one (other names: 4-metylometcatynon, 4-MMC, M-CAT), a synthetic derivative of cathinone [1].

Experienced users of mephedrone have equated its powerful psychostimulant, entactogenic and hallucinogenic properties to those of cocaine, amphetamine, or MDMA (3,4-methylenedioxy-methamphetamine) [2, 3]. However, only a few experimental studies have investigated its behavioral effects on laboratory animals. The first preclinical studies of the effects of mephedrone, published by Kehr et al. [4], reported significant, rapid and dose-dependent increases in both serotonin (5-HT) and dopamine (DA) levels in rats exposed acutely to this compound. This work was extended by the finding that mephedrone causes a rapid decrease in striatal DA and hippocampal 5-HT transporters function. Furthermore, mephedrone inhibits both synaptosomal DA and 5-HT uptake [5]. Recent
investigated not only in humans, but also in animals and used the nicotine-induced locomotor sensitization procedure to investigate behavioral locomotor effects of these drugs. We aimed to examine the interactions between mephedrone and nicotine. Thus, the present study was undertaken to assess oxidative stress processes of acute co-administration of mephedrone and nicotine. Additionally, the present studies were undertaken to investigate behavioral locomotor effects of these drugs. We observed the lack of experimental data concerning the behavioral and biochemical effects relating to the combined use of mephedrone with other psychoactive substances, although the problem seems to be significant. There are currently no studies describing the behavioral effects and antioxidant status (TAS), the activity of catalase (CAT), an antioxidant enzyme, as well as concentration of malondialdehyde (MDA) within the brain tissue were also determined to evaluate the general effects of mephedrone administered alone or with nicotine on the antioxidant barrier. Considering the likelihood that mephedrone is taken as a part of polydrug combination with nicotine, knowledge about drug interactions may be important in the treatment of this kind of addiction.

Materials and Methods

Animals

The experiments were carried out on naive male Swiss mice (Farm of Laboratory Animals, Warsaw, Poland) weighing 20–25 g at the beginning of experiments. The animals were maintained under standard laboratory conditions (12 h light/dark cycle, room temperature 21 ± 1 °C) with free access to tap water and laboratory chow (Agropol, Poland) and were adapted to the laboratory conditions for at least 1 week. Each experimental group consisted of 8–10 animals. All experiments were conducted according to the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and to the European Community Council Directive for the Care and Use of Laboratory Animals of 24 November 1986 (86/609/EEC), and were approved by the local ethics committee. Different mice were used for each drug and time treatment.

Drugs

The following compounds were tested: (−) nicotine hydrochloride tartrate (0.05 and 0.5 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) and mephedrone [(RS)-2-methylamino-1-(4-methylphenyl) propan-1-one, 0.05, 0.1, 0.25, 1, 2.5, 5 and 10 mg/kg; Toronto Research Chemicals Inc.,) Drugs were dissolved in saline solution (0.9 % NaCl), nicotine administered subcutaneously (s.c.) whereas mephedrone was administered intraperitoneally (i.p.) at a volume of 10 ml/kg. Drug doses refer to the salt form. The pH of the nicotine solution was adjusted to 7.0. Fresh drug solutions were prepared on each day of experimentation. Control groups received saline injections of the same volume and via the same route of administration.

The doses of mephedrone and nicotine were chosen based on literature data [26], our recently published articles [27, 28] and preliminary studies.
Experimental Procedure and Treatment

The EPM Procedure

The experimental apparatus was shaped like a “plus” sign and consisted of a central platform (5 × 5 cm), two open arms (30 × 5 cm) and two equal-sized enclosed (30 × 5 × 15 cm) arms opposite to each other. The maze was made of dark Plexiglas, elevated to a height of 50 cm above the floor and illuminated by a dim light.

The used procedure was chosen based on our recently published data [27, 28] and similar to the method of Lister [29]. Anxiolytic activity was indicated by an increase in time spent in the open arms or in the number of entries to the open arms; anxiogenic effects were characterized by a decrease in those measures. The percentage of time spent on the open arms was calculated, just as was the percentage of entries into the open arm. Additionally, the number of enclosed arm entries was recorded as the indicator of motor activity of tested animals. The mice were divided into following groups: nicotine (0.05 mg/kg, s.c.), mephedrone (0.05, 0.1, 0.25, 1, 2.5, 5 and 10 mg/kg, i.p.), saline or mephedrone (0.05 mg/kg, i.p.) co-administered with nicotine (0.05 mg/kg, s.c.). The test was conducted 30 min after nicotine injection or 15 min after mephedrone administration.

The PA Procedure

The apparatus and PA procedure was described in detail in our previous article [28]. It consisted of two-compartment acrylic box with a lighted and darkened compartment. The light chamber was illuminated by a fluorescent light (8 W) and was connected to the dark chamber which was equipped with an electric grid floor. Entrance of the animal to the dark box was punished by an electric foot shock (0.2 mA for 2 s).

On the first day of training (pre-test), mice were placed individually into the light compartment and allowed to explore the light box. After 30 s, the guillotine door was raised to allow the mice to enter the dark compartment. When the mice entered the dark compartment, the guillotine door was closed and an electric foot-shock (0.2 mA) of 2 s duration was delivered immediately to the animal. The latency time for entering the dark compartment was recorded (TL1). If the mouse failed to enter the dark box within 300 s, it was placed into this dark box, the door was closed, and the electric foot shock was delivered to the animal. In this case, TL1 value was recorded as 300 s. In the subsequent trial (retention) 24 h later, the same mouse was again placed individually in the light compartment of the PA apparatus and the time taken to reenter the dark compartment was recorded (TL2). No foot-shock was applied in this trial. If the animal did not enter the dark compartment within 300 s, the test was stopped and TL2 was recorded as 300 s.

The experimental procedure involved examination of memory consolidation (the animals received injections of the substance after pre-test) [30, 31].

During the acute treatment, animals were allocated into the following drug groups: nicotine (0.05 mg/kg, s.c.), mephedrone (1, 2.5, 5 mg/kg, i.p.), saline or mephedrone (2.5 mg/kg, i.p.) co-administered with nicotine (0.05 mg/kg, s.c.). The drugs were administered immediately after pre-test (memory consolidation), and the mice were re-tested 24 h later.

Influence of Mephedrone on the Expression of Nicotine-Induced Locomotor Sensitization

This method was similar to that used in our previous experiments accordingly to the data indicating that nicotine produces robust locomotor sensitization in mice under our laboratory conditions [25]. During the pairing phase (days 1–9), mice received injections of saline (s.c.) or nicotine (0.5 mg/kg, s.c.) every other day for five sessions. The mice remained drug free for 1 week and, on day 16, the same groups of mice were further challenged with nicotine (0.5 mg/kg), mephedrone (1 mg/kg) or saline, respectively. Locomotor activity was recorded for 60 min during the pairing phase (days 1–9) and on the 16th day, immediately after injections. We have chosen the dose of mephedrone not influencing the locomotor activity administered alone

Collection of Tissues

Following the behavioral test conducted after repeated administration of mephedrone, the mice were anesthetized, decapitated and the whole brain was carefully taken out and rinsed in isotonic saline to remove blood. The prefrontal cortex and the hippocampus were rapidly dissected and were used for the study.

Preparation of Tissue Homogenates

The collected tissues were homogenized in 10 volumes of 20 mM Tris-HCl buffer (pH 7.4 on ice for 20 s) and centrifuged at 12,000×g for 10 min at 4 °C. The supernatant was collected and used for further study. TAS, activity of CAT, and MDA level were determined from these supernatants spectrophotometrically with use of HITACHI 2800 apparatus and microplate reader EPOCH.

Determination of Malondialdehyde Concentration (MDA)

MDA was measured by the thiobarbituric acid (TBA) reaction [32]. Briefly, 0.5 ml of tissue homogenate...
supernatant was mixed with 2.5 ml 1.22 M TCA in 0.6 M HCl and allowed to stand for 15 min. Then 1.5 ml of 0.9% TBA was added and the mixture was incubated for 30 min in a boiling water bath. After cooling, 4 ml of n-butanol was added and the mixture was shaken variously. The samples were centrifuged at 1500 g for 10 min and then the absorbance of organic phase was measured at 532 nm with respect to blank (n-butanol alone). The concentration of MDA was read from the standard curve obtained by using malonaldehyde bis-dimethylacetal and expressed as µM of MDA/g of wet tissue.

**Determination of Catalase Activity (CAT)**

The activity of CAT in tissues homogenates was measured with use of OxiSelect Catalase Activity Assay kit (Cell Biolabs, San Diego, CA, USA). The assay was performed according to the manufacturer’s instructions. The absorbance was read at 520 nm. Activities were calculated using a calibration curve and were expressed as µM/min/mg protein.

**Determination of Total Antioxidant Status (TAS)**

TAS of brain homogenates was determined with ready-to-use diagnostic kit TAS by RANDOX (Randox Laboratories Ltd., UK). The method assumes that ABTS [2,2′-Azino-di-(3-ethylbenzthiazoline sulphonate)] produces a radical cation ABTS⁺⁺ when incubated with a peroxidase (hemoglobin) and H₂O₂. The radical cation has a relatively stable blue-green color, however its production can be suppressed by the addition of antioxidants present in the examined samples. Changes in absorption measured at 600 nm are proportional to the antioxidant concentration in the tissues homogenates. Results are expressed in mM Fe/ml tissue.

**Statistical Analysis**

The data were expressed as the mean ± standard error of the mean (SEM). The statistical analyses were performed by the two-way or one-way analysis of variance (ANOVA). Post hoc comparison of means was carried out with the Tukey’s test for multiple comparisons, when appropriate. The confidence limit of p < 0.05 was considered statistically significant.

For the memory related behaviors, changes in the PA performance were expressed as the difference between retention and training latencies and were taken as an index of latency (IL). IL was calculated for each animal and reported as the ratio:

\[ IL = TL2 - TL1 / TL1 \]

**Results**

**Effects of Co-administration of Mephedrone and Nicotine on Anxiety-Related Processes in the EPM Test in Mice**

Figure 1 shows that in animals which had received mephedrone (0.05 mg/kg) in combination with nicotine (0.05 mg/kg) significant effect was revealed on the percentage of open arm entries [two-way ANOVA: treatment (F(1, 34) = 12.91, p < 0.0010) and pre-treatment (F(1, 34) = 8.39, p < 0.0066), without interactions effect (F(1, 34) = 0.91, p = 0.3469)] (Fig. 1a) as well as of time spent on the open arms [two-way ANOVA: treatment (F(1, 33) = 11.69, p < 0.0017) without interactions (F(1, 33) = 8.69, p < 0.0519)] or pre-treatment effect [(F(1, 33) = 1.11, p = 0.2998)] (Fig. 1b). A post hoc analysis showed that an acute dose of nicotine (0.05 mg/kg) and mephedrone (0.05 mg/kg) alone did not affect the percentage of time spent on the open arms and of open-arm entries. However, the post hoc Tukey’s test showed that co-administration of mephedrone and nicotine at the inactive doses decreased both values. Statistically significant decrease in open-arm entries was observed as compared with nicotine-treated (p < 0.05) and mephedrone-treated (p < 0.05) control groups (Fig. 1a). Also, statistically significant decrease in percentage of time spent on the open arms was observed as compared with nicotine-treated (p < 0.05) and mephedrone-treated (p < 0.01) control groups (Fig. 1b).

**Effects of Co-administration of Mephedrone and Nicotine on Memory Related Behaviors in the PA Test**

Figure 2 indicates the effects of co-administration of nicotine (0.05 mg/kg, s.c.) and mephedrone (2.5 mg/kg, i.p.) on memory consolidation during the retention trial in the PA task [two-way ANOVA: pre-treatment (F(1, 28) = 4.55, p = 0.0419), treatment (F(2, 28) = 20.47, p = 0.0001) and interactions (F(2, 28) = 8.82, p = 0.006)]. Statistically significant improvement in memory and learning processes was observed in animals administered with subthreshold doses of nicotine (0.05 mg/kg) and mephedrone (2.5 mg/kg, see also Supplementary Fig. 7) in combination with nicotine- or mephedrone-treated mice (p < 0.001 and p < 0.01, respectively).
Influence of Mephedrone on the Expression of Nicotine-Induced Locomotor Sensitization

Two-way ANOVA of the locomotor response after administration of nicotine (0.05 mg/kg, s.c.) or saline during the pairing phase (day 1 and day 16—challenge) revealed a treatment effect \[ F(4, 69) = 3.35, p < 0.0111 \], a day effect \[ F(1, 69) = 46.22, p < 0.0001 \] and an interaction effect \[ F(4, 69) = 7.95, p < 0.0001 \] (Fig. 3). On the 1st day, one-way ANOVA did not reveal any significant treatment effect \[ F(1, 41) = 1.141, p = 0.3524 \]. On the 16th day, after an additional injection of nicotine, one-way ANOVA revealed a significant treatment effect \[ F(4, 32) = 9.236, p < 0.0001 \]. Indeed, after this last nicotine injection, a significant difference between the response was observed.
as compared to the 1st injection of nicotine (p < 0.001) or with the response to nicotine in animals repeatedly treated with saline (p < 0.001, Tukey’s test) (Fig. 3). Moreover, mephedrone, at the dose of 1 mg/kg injected on the day 16 to the nicotine-pretreated group significantly increased the locomotor activity of mice as compared to the first injection of nicotine (p < 0.001) and to the group of animals repeatedly treated with saline and challenged with mephedrone (p < 0.01, Tukey’s test). We have chosen the dose of mephedrone not influencing the locomotor activity administered alone as measured in the actimeter cages and the EPM paradigm as the number of enclosed arm entries (Supplementary Fig. 8; Supplementary Table 1).

**Effects of Mephedrone on Oxidative Stress Biomarkers**

**Effects of Co-administration of Mephedrone and Nicotine on Oxidative Stress Indicators**

The changes in value of TAS, activity of CAT and concentration of MDA were found after co-administration of mephedrone and nicotine in the examined brain structures. Figure 4 shows the activities of MDA after co-administration of mephedrone and nicotine in the hippocampus [two-way ANOVA: pre-treatment (F(1, 51) = 66.67, p < 0.0001), and treatment (F(2, 51) = 10.30, p = 0.0001), without interaction effect (F(2, 51) = 0.32, p = 0.7250)] and the prefrontal cortex [two-way ANOVA: pre-treatment (F(1, 50) = 9.34, p = 0.0036) and treatment (F(2, 50) = 9.17, p = 0.0004) without interaction effect (F(2, 50) = 0.81, p = 0.4528)]. The post hoc Tukey’s test revealed that an acute injection of nicotine at the dose of 0.05 mg/kg significantly decreased the activity of CAT in both examined structures (p < 0.05) versus saline-treated control group. Also, mephedrone (2.5 mg/kg) statistically

(F(2, 50) = 0.10, p = 0.9012)]. The post hoc Tukey’s test revealed that an acute injection of mephedrone at the dose of 2.5 mg/kg significantly increased level of MDA in the hippocampus and prefrontal cortex (p < 0.05) versus saline-treated control group. The same effects have been seen after the dose of 5 mg/kg in both brain areas (Supplementary Fig. 9). Also, nicotine (0.05 mg/kg) significantly increased the concentration of the marker of lipids peroxidation processes in the prefrontal cortex (p < 0.001). Moreover, co-administration of nicotine (0.05 mg/kg) and mephedrone in both used doses (0.05 and 2.5 mg/kg) led to significant increase in MDA concentration in the prefrontal cortex (nicotine + mephedrone at the dose of 0.05 mg/kg—p < 0.001; nicotine + mephedrone at the dose of 2.5 mg/kg—p < 0.01) in comparison with appropriate mephedrone-treated group.

Figure 5 shows the activities of CAT after co-administration of mephedrone and nicotine in the hippocampus [two-way ANOVA: pre-treatment (F(1, 50) = 21.82, p = 0.0001), and treatment (F(2, 50) = 7.94, p = 0.0001), without interaction effect (F(2, 50) = 0.81, p = 0.4528)] and the prefrontal cortex [two-way ANOVA: pre-treatment (F(1, 50) = 16.14, p = 0.0002) and treatment (F(2, 50) = 7.36, p = 0.0017) without interaction effect (F(2, 50) = 0.97, p = 0.3851)]. The post hoc Tukey’s test revealed that an acute injection of nicotine at the dose of 0.05 mg/kg significantly decreased the activity of CAT in both examined structures (p < 0.05) versus saline-treated control group. Also, mephedrone (2.5 mg/kg) statistically

(F(2, 50) = 0.10, p = 0.9012)]. The post hoc Tukey’s test revealed that an acute injection of mephedrone at the dose of 2.5 mg/kg significantly increased level of MDA in the hippocampus and prefrontal cortex (p < 0.05) versus saline-treated control group. The same effects have been seen after the dose of 5 mg/kg in both brain areas (Supplementary Fig. 9). Also, nicotine (0.05 mg/kg) significantly increased the concentration of the marker of lipids peroxidation processes in the prefrontal cortex (p < 0.001). Moreover, co-administration of nicotine (0.05 mg/kg) and mephedrone in both used doses (0.05 and 2.5 mg/kg) led to significant increase in MDA concentration in the prefrontal cortex (nicotine + mephedrone at the dose of 0.05 mg/kg—p < 0.001; nicotine + mephedrone at the dose of 2.5 mg/kg—p < 0.01) in comparison with appropriate mephedrone-treated group.

![Fig. 4 Effect of co-administration of mephedrone (0.05 or 2.5 mg/kg, i.p.) and nicotine (0.05 mg/kg, s.c.) on concentration of MDA in the hippocampus and prefrontal cortex of mice. Data are presented as the mean ± SEM; n = 8–10; *p < 0.05; ***p < 0.001 versus saline-treated control group; ##p < 0.01 versus mephedrone 2.5 mg/kg-treated control group; & & & p < 0.001 versus mephedrone 0.05 mg/kg-treated control group; Tukey’s test](image)

![Fig. 5 Effect of co-administration of mephedrone (0.05 or 2.5 mg/kg, i.p.) and nicotine (0.05 mg/kg, s.c.) on activity of CAT in the hippocampus and prefrontal cortex of mice. Data are presented as the mean ± SEM; n = 8–10; *p < 0.05; **p < 0.01 versus saline-treated control group; ##p < 0.05 versus mephedrone 2.5 mg/kg-treated control group; & & & & & p < 0.001 versus mephedrone 0.05 mg/kg-treated control group; #p < 0.05 versus nicotine-treated control group; Tukey’s test](image)
decreased the activity of the enzyme in the hippocampus and prefrontal cortex \((p < 0.01)\) (see also the same effects for the dose of 5 mg/kg, Supplementary Fig. 10). Moreover, co-administration of nicotine \((0.05 \text{ mg/kg})\) and mephedrone \((0.05 \text{ mg/kg})\) significantly decreased CAT activity in the hippocampus \((p < 0.05)\) in comparison to mephedrone-treated group. Furthermore, significant decrease in CAT level was observed in the hippocampus when mephedrone \((2.5 \text{ mg/kg})\) was co-administered with nicotine versus mephedrone-treated mice \((p < 0.05)\) as well as in the prefrontal cortex \((p < 0.05)\) versus nicotine-treated mice.

Figure 6 shows the values of TAS after co-administration of mephedrone and nicotine in the hippocampus \([\text{two-way ANOVA: treatment} (F(2, 54) = 11.54, p < 0.0001)\] without pre-treatment \((F(1, 54) = 1.46, p = 0.2300)\), and interaction effect \((F(2, 54) = 0.01, p = 0.9960)\)\] and the prefrontal cortex \([\text{two-way ANOVA: pre-treatment} (F(1, 54) = 33.15, p < 0.0001)\] and treatment \((F(2, 54) = 4.54, p = 0.0150)\) without interaction effect \((F(2, 54) = 0.52, p = 0.5992)\)\]. The post hoc Tukey’s test revealed that an acute injection of nicotine at the dose of 0.05 mg/kg significantly decreased TAS values in the prefrontal cortex \((p < 0.01)\) versus saline-treated control group. Also, mephedrone \((2.5 \text{ mg/kg})\) significantly decreased the concentration of antioxidants in the hippocampus \((p < 0.05)\) (see also the same effects of the dose of 5 mg/kg in both structures, Supplementary Fig. 11). Moreover, co-administration of nicotine \((0.05 \text{ mg/kg})\) and mephedrone \((2.5 \text{ mg/kg})\) led to significant decrease in TAS value in the hippocampus \((p < 0.01)\) and prefrontal cortex \((p < 0.05)\) in comparison with nicotine-treated group. Furthermore, significant decrease in TAS level was also observed when mephedrone \((2.5 \text{ mg/kg})\) was co-administered with nicotine in the prefrontal cortex \((p < 0.01)\) versus mephedrone-treated mice.

### Discussion

This study attempts for the first time to show the acute, behavioral effects of mephedrone and nicotine co-administration using animal experimental models. In addition, we assessed the effect of the combined administration of mephedrone and nicotine on oxidative status in the brain. Our results showed that animals treated with mephedrone and nicotine at the subthreshold doses demonstrated elevated level of anxiety in the EPM test and displayed pro-cognitive behaviors in the PA paradigm. Also, the results confirmed that repeated daily injections of nicotine produced progressive increases in locomotor activity in mice, especially to a subsequent nicotine challenge. One of the main findings of the current study was that mephedrone, administered at the dose not influencing the locomotor activity of mice, enhanced the expression of nicotine-induced sensitization. Indeed, nicotine-experienced mice showed an increased response to the mephedrone injection compared with both the first pairing day and the response to acute mephedrone challenge in animals pre-exposed to saline. Additionally, our results indicated that mephedrone as well as nicotine exerted strong pro-oxidative effects. First, the research proved a decrease in total antioxidant status, i.e., general concentrations of all antioxidant molecules present in the samples of the hippocampus and the prefrontal cortex. Then, decrease in CAT activity confirmed that the oxidative action of the drugs was associated with overproduction of reactive oxygen species; here \(\text{H}_2\text{O}_2\), as CAT is involved in hydrogen peroxide disintegration to water and oxygen. Finally, an increase in MDA concentration revealed induction of oxidative damages to brain lipids. Additionally, co-administration of both psychoactive substances intensified the oxidative changes in particular structures of the brain.

Many of the available studies indicate that amphetamines increase neuropsychiatric symptoms like anxiety in animal models as well as humans \([34–37]\). On the other hand, den Hollander et al. \([38]\) observed that anxiety- and depression-related behaviors did not appear after mephedrone administration using binge like regimen. However, our studies revealed that this compound administered alone exerted a strong anxiogenic action in the dose range of 0.25–10 mg/kg, but the dose of 0.05 mg/kg did not influence the observed effect.

Our previous results have shown that a single injection of nicotine at the dose of 0.1 mg/kg had a significant
administration is normally oral, nasal or rectal [1–3]. Times lead to local necrotic lesions. For this reason, human venous injections of mephedrone in humans (even only 2–3 intraperitoneal injections. It is known that repeated intravascular administration of mephedrone by intravenous injections of mephedrone in humans (even only 2–3 times) lead to local necrotic lesions. For this reason, human administration is normally oral, nasal or rectal [1–3].

Another aim of the present research was to record the interaction between mephedrone and nicotine at the level of cognitive processes at the consolidation trial, using the PA test in mice. Evidences show that memory deficits occur after chronic use of psychostimulants, and the neurodegenerative effects of these compounds may lead to cognitive disabilities [39, 40]. Recent research also indicates that chronic or subchronic administration of mephedrone causes a reduction in memory function in rats [7, 38, 41]. However, other data indicate that mephedrone increases cognitive function after an acute administration similarly to other stimulants [42]. Also, series of study show that a post-training injection of d-amphetamine improves memory storage processes in the consolidation phase [43]. Our studies correspond with these results, as an acute administration of mephedrone, at the highest dose (5 mg/kg), improved memory processes in the consolidation trial. In animals, step-through latency to enter the dark compartment was significantly longer in the 24 h test, showing that they remembered the training session. Furthermore, in the current study we revealed that co-administration of subthreshold doses of mephedrone and nicotine produced an improvement in the memory processes in animals during the consolidation phase.

It is also well known that nicotine induces cognitive effects [44–46]. According to the previous study, we chose the subthreshold dose of nicotine (0.05 mg/kg) which has not affected memory and learning processes [28]. It should be noted that experiments with post-training drug administration have provided strong evidence that the memory enhancing effect of the drug is not a consequence of influences on acquisition processes or performance, because rodents are drug-free during the pre-test and test [47, 48]. Moreover, when the consolidation processes are measured, the stimulation of locomotor activity by mephedrone at the dose 5 mg/kg does not affect the obtained result.

Two anatomic structures have been recognized as important players in memory consolidation, e.g., the hippocampus and neocortex. These processes are mediated mainly by NMDA receptor activation and by dopaminergic systems [49, 50]. Additionally, GABA, noradrenalin, and 5-HT are also involved in the memory modulation [12, 51]. The neurobiological mechanisms of cognitive-enhancement by nicotine are well-characterized, and among all central nAChR subtypes, both the αβ2 combination and the α7 subunits appear to play important roles in memory-related responses [52]. The prefrontal cortex and the hippocampus seem to be important target sites for the nicotine effects on memory function [53, 54]. It is possible to suggest that the synergistic effect of an acute administration of nicotine and mephedrone on cognitive processes observed in our experiments may be explained by the influence of both drugs on dopaminergic and serotoninergic neurotransmission in the brain. Unfortunately, previously mentioned brain structures, e.g., hippocampus and prefrontal cortex are very susceptible to oxidative damage. Generally, a lot of evidence exists that intensification of oxidative processes is the primary cause of neurodegeneration. Indeed, mephedrone administered alone at the higher doses (2.5 and 5 mg/kg) as well as co-administration of mephedrone and nicotine induced oxidative stress observed as an increase in MDA levels and a decrease in.
TAS values and CAT activity in both structures. Therefore, we could expect impairment of memory processes. However, mephedrone-induced oxidative stress may not be long lasting, taking into consideration strong defense mechanisms of healthy organisms of experimental animals, as in the experiment only single doses of the drug were used. It shows proper functioning of an antioxidant system, which consists of low-molecular weight endogenous antioxidants, antioxidant proteins and enzymes as well as many regulator proteins that mediate adaptive responses to oxidative stress [55]. Therefore, such a one-time pro-oxidative intervention may stimulate antioxidant barrier to enhance release of intracellular antioxidants as well as up-regulation of ROS-metabolizing enzymes expression to counteract similar episodes in future. In our experiments, the memory processes were investigated 24 h after drug injection, when we did not observe changes in antioxidant status of brain tissue (data not shown). The attempts to understand the mechanisms underlying adaptive cell responses to mephedrone as well as nicotine-induced oxidative stress will provide new insight into development of neuroprotective treatment among psychoactive drug users and effective strategies for withdrawal therapy.

Furthermore, behavioral sensitization observed in our experiments, refers to a phenomenon by which the repeated use of a drug produces a progressive increase in the psychomotor response and has been implicated in the development of drug addiction [56–59] and drug-induced psychosis [60]. Behavioral sensitization can persist for several weeks and results from neuroplasticity in mesolimbic dopaminergic pathways [58, 61, 62]. Several drugs have been found to induce behavioral sensitization including cocaine, amphetamine, opiates [62] and nicotine [63]. It has been shown that repeated treatment with an addictive drug produces cross-sensitization defined as hyper-responsiveness to one psychostimulant after pre-exposure to a different drug [56, 64–66]. We used the nicotine-induced locomotor sensitization procedure to examine if nicotine-experienced mice show hyperactivity after an acute mephedrone administration. Our results confirmed that repeated daily injections of nicotine produced progressive increases in locomotor activity in mice, especially to a subsequent nicotine challenge [35, 67, 68]. Experimental data show that the expression of both acute and sensitizing locomotor effects of nicotine is coincident with functional changes in mesolimbic dopaminergic neurotransmission [69]. Concerning mephedrone, this drug induces short-term hyperlocomotion due to increased DA and endogenous 5-HT levels [4, 26, 70]. One of the main findings of the present study was the development of locomotor hyperactivity to mephedrone in nicotine-sensitized mice. We can’t exclude the existence of the full cross-sensitization phenomenon between nicotine and mephedrone, due to their similar neural pathways affected, but studies concerning the ability of mephedrone to elucidate behavioral sensitization are still unexplored and further analysis are needed.

In summary, abuse of psychoactive drugs constitutes a major problem worldwide, especially among young adults. The structural similarities of methcathinone and methylene with mephedrone suggest that we may still not appreciate the long-term risks of mephedrone use. There is also a great tendency for drug users to engage in simultaneous poly-substance use. Thus, polydrug use may be the rule rather than exception. Our study has shown the existence of strong interaction after an acute, concomitant administration of nicotine and mephedrone in anxiety, memory and locomotor sensitization experimental paradigms. Co-administration of subthreshold doses of both drugs exerts an anxiogenic effect and memory improvement. Both substances, mephedrone and nicotine, have been found to exert strong pro-oxidant effect on brain tissue. This influence was even stronger when both drugs were administered together. Finally, locomotor hyperactivity between nicotine and mephedrone when mice were pretreated with nicotine was obtained. Understanding the consequences of co-administration of psychoactive substances on the CNS and oxidative processes in the brain provide the toxicological significance, and may be useful in polydrug intoxication treatment. However, further research is required to determine long-term effects of mephedrone.

Acknowledgments This study was supported by Grant No. 2013/11/B/NZ7/04837 from the National Science Centre, Poland and by the statutory activity of the Medical University of Lublin, Poland.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standard All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of National Institute of Health Guidelines for the Care and Use of Laboratory Animals and to the European Community Council Directive for the Care and Use of Laboratory Animals of 24 November 1986 (86/609/EEC), and were approved by the local ethics committee. This article does not contain any studies with human participants performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SH (2011) Clinical characteristics of mephedrone
toxicity reported to the UK National Poisons Information Service. Emerg Med J 28:686–689
2. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre M, Torrenes D, Demetrovics Z, Ghose AH (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical pharmacological and clinical issues. Psychopharmacology 214:593–602
3. Winstock AR, Marsden J, Mitcheson L (2010) What should be done about mephedrone? BMJ 340:c1605
4. Kehr JF, Ichinoso S, Yoshitake M, Goiny T, Sievertsson F, Nyberg T, Yoshitake T (2011) Mephedrone compared to MDMA (ecstasy) and amphetamine rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949–1958
5. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339(2):530–536
6. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22(3):231–236
7. Motby CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J, Hicks C, Kendig MD, Wyatt N, Callaghan PD, McGregor IS (2012) Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 7(9):e45473. doi:10.1371/journal.pone.0045473
8. Angoa-Pérez M, Kane MJ, Briggs DJ, Francescutti DM, Sykes CE, Shah MM, Mohammed AM, Thomas DM, Kuhn DM (2012) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem 125(1):102–110. doi:10.1111/jnc.12114
9. Angoa-Pérez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, Thomas DM, Kuhn DM (2012) Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 120(6):1097–1107. doi:10.1111/j.1471-4159.2011.07632.x
10. Angoa-Pérez M, Kane MJ, Herrera-Mundo N, Francescutti DM, Kuhn DM (2014) Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci 97(1):31–36. doi:10.1016/j.lfs.2013.07.015
11. Gonçalves J, Baptista S, Silva AP (2014) Psychostimulants and brain dysfunction: a review of the relevant neurotoxic effects. Neuropharmacology 87:135–149. doi:10.1016/j.neuropharm.2014.01.006
12. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92–98
13. Herman AI, Sofuoglu M (2010) Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep 12:433–440
14. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633–640
15. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, Rose JE (2009) Nicotinic α7- or β2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 196:207–213
16. Marubio LM, Arroyo-Jimenez MDM, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d’Exaerde A, Huchet M, Damaj MI. Changeux JP (1999) Reduced antioxidation in mice lacking neuronal nicotinic receptor subunits. Nature 398:805–810
17. File SE, Cheeta S, Kenny PJ (2000) Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 393:231–236
18. Hayase T (2011) Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol 11:6
19. Biala G, Polak P, Michalak A, Kruk-Słomka M, Budzynska B (2014) Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice. Pharmacol Rep 66(2):212–222
20. Budzynska B, Polak P, Biala G (2012) Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm. Behav Brain Res 228(1):144–150
21. Duni JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446
22. Kruk-Słomka M, Budzynska B, Biala G (2012) Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 64(5):1066–1080
23. Malin DH (2001) Nicotine dependence studies with a laboratory model. Pharmacol Biochem Behav 70:551–559
24. Yildiz D (2004) Nicotine its metabolism and an overview of its biological effects. Toxicon 43:619–632
25. Biala G, Stania K (2010) Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol Biochem Behav 96(2):141–147
26. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butyline mephedrone and methylene. Br J Pharmacol 167(2):407–420
27. Biala G, Budzynska B (2006) Effects of acute and chronic nicotine on elevated plus maze in mice: involvement of calcium channels. Life Sci 79(1):81–88
28. Budzynska B, Boguszewska-Czubara A, Kruk-Słomka M, Skalicka-Woźniak K, Michalak A, Musik I, Biala G, Głowniak K (2013) Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice. Physiol Behav 122:46–55
29. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92(2):180–185
30. Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 650:240–248
31. Javadi-Paydar M, Zakeri M, Norouzi A, Rastegar H, Mirazi N, Dehpour A (2012) Involvement of nitric oxide in granisetron improving effect on scopolamine-induced memory impairment in mice. Brain Res Rev 1429:61–71
32. Ledwozyw A, Michalak J, Stepień A, Kadziółka A (1986) The synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 11:6
33. Chimakurthy J, Talasila M (2010) Effects of curcumin on pentyleneetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 3:239–244
34. Lenz J, Brown J, Flagg S, Oh R, Batts K, Ditzler T, Johnson J (2013) Cristalius: a case in designer drugs. Mil Med 178(7):e893–e895
35. McCord K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use and cognition and mood. Psychopharmacology 173:434–439
36. Moon M, Do KS, Park J, Kim D (2007) Memory impairment in methamphetamine dependent patients. Int J Neurosci 117:1–9
37. Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34(4):363–367
38. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpí ER (2013) Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylene and mephedrone. Pharmacol Biochem Behav 103:501–509
39. Ciccarone D (2011) Stimulant abuse: pharmacology cocaine methamphetamine treatment attempts at pharmacotherapy. Prim Care 38:41–58
40. McKetin R, Mattick RP (1997) Attention and memory in illicit amphetamine users. Drug Alcohol Depend 48(3):235–242
41. Motley CP, Hunt GE, Bowen MT, Artiss S, McGregor IS (2012) Mephedrone (+-methylmethcathinone ‘meow’): acute behavioral effects and distribution of Fos expression in adolescent rats. Addict Biol 17(2):409–422
42. Nyberg F (2012) Cognitive impairments in drug addicts. In: González-Quevedo A (ed) Brain damage—bridging between basic research and clinics. InTech. doi:10.5772/37661
43. Strupp BJ, Bunsey M, Levitsky D, Kesler M (1991) Time-dependent effects of post-trial amphetamine treatment in rats: evidence for enhanced storage of representational memory. Behav Neural Biol 56(1):62–76
44. Kenney JW, Adoff MD, Wilkinson DS, Gould TJ (2011) The effects of acute chronic and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology 217(3):353–365. doi:10.1007/s00213-011-2283-7
45. Kenney JW, Gould TJ (2008) Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 38:101–121
46. Kenney JW, Gould TJ (2008) Nicotine enhances context learning but not context-shock associative learning. Behav Neurosci 122:1158–1165
47. Doty BA, Doty LA (1966) Facilitative effects of amphetamine on avoidance conditioning in relation to age and problem difficulty. Psychopharmacology 9(3):234–241
48. Krivanek JA, McCaugh JL (1969) Facilitating effects of pre- and post-trial amphetamine administration on discrimination learning in mice. Agents Actions 1(2):36–42
49. Sesack SR, Pickel VM (1990) In the rat medial nucleus accumens hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527(2):266–279
50. Tokunaga M, Seneca N, Shin RM, Maeda J, Okauchi T, Nagai Y, Zhang MR, Nakao R, Ito H, Innis RB, Halldin C, Suzuki K, Higuchi M, Suhara T (2009) Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 29(6):1887–1896
51. Levin ED, Rezvani AH (2007) Nicotinic interactions with antipsychotic drugs models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 74:1182–1191
52. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology 108:417–443
53. Picciotto MR, Caldarone BJ, King SL, Zachariou V (2000) Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22:451–465
54. Sparks JA, Pauly JR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57BL/6 mice. Psychopharmacology 141:145–153
55. Ma Q (2014) Advances in mechanisms of anti-oxidation. Discov Med 17(93):121–130
56. Dafny N, Yang PB (2006) The role of age genotype sex and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 68:393–405
57. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223–244
58. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18(3):247–291
59. Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders EJ, Schoffelen AN (1999) A single exposure to amphetamine is sufficient to induce long-term behavioral neuroendocrine and neurochemical sensitization in rats. J Neurosci 19:9579–9586
60. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396(2):157–198
61. Hope BT, Simmons DE, Mitchell TB, Kreuder JD, Mattson BJ (2006) Cocaine-induced locomotor activity and Fos expression in nucleus accumbens are sensitized for 6 months after repeated cocaine administration outside the home cage. Eur J Neurosci 24(3):867–875
62. Vanderschuren LJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151(2–3):99–120
63. DiFranza JR, Wellman RJ (2007) Sensitization to nicotine: how the animal literature might inform future human research. Nicotine Tob Res 9:9–20
64. Akimoto K, Hammadari T, Kazahaya Y, Akiyama K, Otsuki S (1990) Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine-an in vivo dialysis study in freely moving rats. Brain Res 507:344–346
65. Cunningham ST, Kelley AE (1992) Evidence for opiate-dopamine cross-sensitization in nucleus accumbens: studies of conditioned reward. Brain Res Bull 29:675–680
66. Aizenstein ML, Segal DS, Kuczynski R (1990) Repeated amphetamine and fencamfamine: sensitization and reciprocal cross-sensitization. Neuropsychopharmacology 3:283–290
67. Clarke PB, Kumar R (1983) Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80:587–594
68. Clarke PB, Kumar R (1983) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329–337
69. Baker LK, Mao D, Chi H, Govind AP, Vallejo YF, Iacoviello M, Herrera S, Cotrigh JJ, Green WN, McGehee DS, Vezina P (2013) Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitizes locomotor responding to the drug. Eur J Neurosci 37(6):1004–1011
70. Lisek R, Xu W, Yuvasheva E, Chiu Y, Reitz AB, Liu-Chen L, Rawls SM (2012) Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 126:257–262